Industry Overview

UK animal vaccine market was valued at $712.0 million in 2025 and is projected to reach $1,318.4 million by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035). The UK animal vaccine market is witnessing steady growth, supported by the country’s strong veterinary healthcare infrastructure, stringent animal health regulations, and increasing awareness regarding disease prevention in both livestock and companion animals. The market is driven by rising incidences of infectious animal diseases, growing demand for high-quality animal-derived food products, and expanding pet ownership across the United Kingdom. Government-backed disease surveillance and vaccination initiatives, led by the Department for Environment, Food & Rural Affairs (DEFRA) and the Animal and Plant Health Agency (APHA), continue to reinforce preventive healthcare measures in livestock and aquaculture. These efforts are complemented by strict biosecurity policies and regulatory oversight to minimize zoonotic disease risks and ensure food safety standards. Technological advancements in recombinant and vector-based vaccines, along with increased investment in research and development, are further strengthening market expansion. Additionally, the growing trend toward preventive veterinary care, particularly among companion animal owners, is contributing to higher vaccination coverage rates. As sustainability, animal welfare, and productivity remain central to UK agricultural policy, animal vaccination continues to play a vital role in safeguarding animal health and optimizing farm output.

Market Dynamics

Rising Focus on Livestock Disease Prevention and Food Security

The UK livestock sector is increasingly prioritizing preventive vaccination strategies to mitigate the economic impact of infectious outbreaks such as bovine respiratory diseases, avian influenza, and swine-related infections. Regulatory enforcement of vaccination and monitoring programs supports herd health management and reduces dependency on antibiotics. Export-oriented meat and dairy producers are adopting structured immunization programs to comply with international trade standards and maintain supply chain stability. As food safety and traceability requirements tighten, vaccination programs are becoming integral to sustainable livestock management practices.

Growth in Companion Animal Healthcare and Advanced Vaccine Technologies

The UK has one of the highest pet ownership rates in Europe, driving sustained demand for companion animal vaccines. Pet owners are increasingly seeking comprehensive preventive care, including core and non-core vaccinations for dogs and cats. Veterinary clinics are expanding their service portfolios with combination and long-duration vaccines to improve compliance and convenience. Meanwhile, advances in recombinant, subunit, and DNA-based vaccine technologies are enhancing vaccine safety profiles and immunogenicity. These innovations are particularly valuable in managing emerging infectious diseases and improving overall disease control strategies across species.

Market Segmentation

• Based on the type, the market is segmented into porcine vaccines, poultry vaccines, livestock vaccines, aquaculture vaccines, companion animal vaccines, and other animal vaccines.
• Based on the technology, the market is segmented into live attenuated vaccine, killed/inactive vaccine, recombinant vaccine, vectored vaccine, subunit vaccine, DNA vaccine, chimeric vaccine, and others.

Livestock Vaccines Segment to Hold a Significant Market Share

The livestock vaccines segment is expected to account for a substantial share of the UK animal vaccine market, driven by the country’s well-established cattle and poultry industries. Preventive vaccination programs are widely adopted to manage endemic and emerging diseases that impact productivity and profitability. Ongoing monitoring and disease eradication efforts, supported by national animal health policies, are encouraging routine immunization across dairy and beef farms. In addition, the integration of advanced vaccine technologies is improving herd immunity levels and minimizing economic losses associated with disease outbreaks. As regulatory frameworks continue to emphasize disease prevention and antibiotic stewardship, livestock vaccination is projected to remain a cornerstone of the UK animal health landscape.

Live Attenuated and Recombinant Vaccines Gaining Technological Prominence

Among technology segments, live attenuated vaccines continue to maintain a strong presence due to their proven efficacy and long-standing use in livestock and poultry applications. However, recombinant and vectored vaccines are gaining increasing traction, supported by advancements in biotechnology and growing demand for safer and more targeted immunization solutions. These next-generation vaccines offer improved safety profiles, enhanced stability, and reduced adverse reactions, making them particularly suitable for companion animals and high-value livestock. As research investments accelerate and innovation pipelines expand, technologically advanced vaccine platforms are expected to contribute significantly to future market growth.

Market Players Outlook

The major companies operating in the UK animal vaccine market include Benchmark Holdings plc, Elanco Animal Health UK, Merck Sharp & Dohme Limited, Phibro Animal Health Corporation, Zoetis UK Limited., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In July 2025, Zoetis expanded its vaccine manufacturing capabilities in the United Kingdom to strengthen supply resilience for livestock and companion animal vaccines. The expansion supports increasing domestic demand and enhances distribution efficiency across Europe.
• In May 2025, MSD Animal Health introduced an upgraded recombinant vaccine portfolio in the UK, aimed at improving disease protection in cattle and poultry while supporting antibiotic reduction initiatives within commercial farming systems.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the UK animal vaccine
• Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.